Acadian Asset Management LLC Boosts Stake in 10x Genomics $TXG

Key Points

• Acadian Asset Management LLC increased its stake in 10x Genomics (NASDAQ:TXG) by 167.7% during the first quarter, holding 406,405 shares worth $3,543,000.
• Many institutional investors, including UBS AM and Millennium Management LLC, have significantly boosted their positions in 10x Genomics, contributing to 84.68% of the stock being owned by such investors.
• The company reported earnings of $0.28 per share for the latest quarter, surpassing estimates and marking a revenue increase of 12.9% year-over-year.

Acadian Asset Management LLC lifted its holdings in 10x Genomics (NASDAQ:TXG - Free Report) by 167.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 406,405 shares of the company's stock after buying an additional 254,607 shares during the quarter. Acadian Asset Management LLC owned 0.33% of 10x Genomics worth $3,543,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of TXG. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in 10x Genomics by 235.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,103,768 shares of the company's stock worth $62,016,000 after purchasing an additional 4,987,195 shares in the last quarter. Millennium Management LLC boosted its position in 10x Genomics by 434.5% during the first quarter. Millennium Management LLC now owns 5,377,492 shares of the company's stock worth $46,946,000 after purchasing an additional 4,371,327 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its position in 10x Genomics by 3,619.6% during the first quarter. Jacobs Levy Equity Management Inc. now owns 1,166,723 shares of the company's stock worth $10,185,000 after purchasing an additional 1,135,356 shares in the last quarter. Iron Triangle Partners LP purchased a new stake in 10x Genomics during the first quarter worth $8,730,000. Finally, Two Sigma Investments LP boosted its position in 10x Genomics by 291.2% during the fourth quarter. Two Sigma Investments LP now owns 1,319,487 shares of the company's stock worth $18,948,000 after purchasing an additional 982,203 shares in the last quarter. 84.68% of the stock is currently owned by hedge funds and other institutional investors.

10x Genomics Price Performance

Shares of NASDAQ TXG opened at $12.64 on Monday. 10x Genomics has a 1-year low of $6.78 and a 1-year high of $24.38. The business has a 50-day moving average of $13.21 and a 200-day moving average of $10.81. The company has a market capitalization of $1.57 billion, a price-to-earnings ratio of -18.06 and a beta of 2.00.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.63. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.The company had revenue of $172.91 million during the quarter, compared to the consensus estimate of $139.36 million. During the same quarter in the prior year, the business earned ($0.32) earnings per share. The company's revenue was up 12.9% compared to the same quarter last year. 10x Genomics has set its Q3 2025 guidance at EPS. Research analysts expect that 10x Genomics will post -1.43 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Adam Taich sold 22,315 shares of the business's stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $307,723.85. Following the transaction, the chief financial officer owned 309,273 shares in the company, valued at approximately $4,264,874.67. The trade was a 6.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Serge Saxonov sold 9,348 shares of the business's stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $128,908.92. Following the completion of the transaction, the chief executive officer owned 945,892 shares in the company, valued at approximately $13,043,850.68. This trade represents a 0.98% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 39,149 shares of company stock worth $539,865. 10.03% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on TXG shares. Wall Street Zen cut 10x Genomics from a "buy" rating to a "hold" rating in a report on Saturday. UBS Group boosted their price target on 10x Genomics from $12.00 to $13.00 and gave the stock a "neutral" rating in a report on Friday, August 8th. Zacks Research cut 10x Genomics from a "strong-buy" rating to a "hold" rating in a report on Friday, September 5th. Piper Sandler started coverage on 10x Genomics in a report on Thursday. They issued a "neutral" rating and a $15.00 price target for the company. Finally, Bank of America boosted their price target on 10x Genomics from $12.00 to $13.00 and gave the stock a "neutral" rating in a report on Thursday, June 26th. Six analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, 10x Genomics has a consensus rating of "Hold" and a consensus price target of $13.65.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.